Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1890 1
1946 1
1947 1
1948 4
1949 2
1950 2
1951 2
1952 1
1953 4
1954 1
1955 1
1956 2
1958 1
1959 4
1960 9
1961 4
1962 4
1963 8
1964 5
1966 7
1967 2
1968 7
1969 8
1970 10
1971 6
1972 3
1973 8
1974 4
1975 12
1976 12
1977 19
1978 17
1979 17
1980 24
1981 29
1982 24
1983 38
1984 32
1985 24
1986 42
1987 31
1988 34
1989 27
1990 54
1991 50
1992 63
1993 50
1994 33
1995 44
1996 55
1997 46
1998 57
1999 58
2000 61
2001 59
2002 79
2003 59
2004 76
2005 81
2006 67
2007 89
2008 101
2009 72
2010 102
2011 101
2012 111
2013 102
2014 99
2015 114
2016 115
2017 104
2018 104
2019 122
2020 119
2021 137
2022 170
2023 120
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

3,109 results

Results by year

Filters applied: . Clear all
Page 1
Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Moreau P, et al. Among authors: goldberg jd. N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35661166 Free PMC article. Clinical Trial.
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Chari A, et al. Among authors: goldberg jd. N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10. N Engl J Med. 2022. PMID: 36507686 Clinical Trial.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Berdeja JG, et al. Among authors: goldberg jd. Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24. Lancet. 2021. PMID: 34175021 Clinical Trial.
A review of the pathophysiology of recurrent implantation failure.
Franasiak JM, Alecsandru D, Forman EJ, Gemmell LC, Goldberg JM, Llarena N, Margolis C, Laven J, Schoenmakers S, Seli E. Franasiak JM, et al. Among authors: goldberg jm. Fertil Steril. 2021 Dec;116(6):1436-1448. doi: 10.1016/j.fertnstert.2021.09.014. Epub 2021 Oct 19. Fertil Steril. 2021. PMID: 34674825 Free article. Review.
Fundamentals of Intervertebral Disc Degeneration.
Kirnaz S, Capadona C, Wong T, Goldberg JL, Medary B, Sommer F, McGrath LB Jr, Härtl R. Kirnaz S, et al. Among authors: goldberg jl. World Neurosurg. 2022 Jan;157:264-273. doi: 10.1016/j.wneu.2021.09.066. World Neurosurg. 2022. PMID: 34929784
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Martin T, et al. Among authors: goldberg jd. J Clin Oncol. 2023 Feb 20;41(6):1265-1274. doi: 10.1200/JCO.22.00842. Epub 2022 Jun 4. J Clin Oncol. 2023. PMID: 35658469 Free PMC article.
Lumbar Herniated Disc.
Carnevale JA, Goldberg JL, Schwarz J. Carnevale JA, et al. Among authors: goldberg jl. World Neurosurg. 2022 Oct;166:52-53. doi: 10.1016/j.wneu.2022.07.059. Epub 2022 Jul 19. World Neurosurg. 2022. PMID: 35863642 No abstract available.
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Usmani SZ, et al. Among authors: goldberg jd. Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10. Lancet. 2021. PMID: 34388396 Clinical Trial.
Solving neurodegeneration: common mechanisms and strategies for new treatments.
Wareham LK, Liddelow SA, Temple S, Benowitz LI, Di Polo A, Wellington C, Goldberg JL, He Z, Duan X, Bu G, Davis AA, Shekhar K, Torre A, Chan DC, Canto-Soler MV, Flanagan JG, Subramanian P, Rossi S, Brunner T, Bovenkamp DE, Calkins DJ. Wareham LK, et al. Among authors: goldberg jl. Mol Neurodegener. 2022 Mar 21;17(1):23. doi: 10.1186/s13024-022-00524-0. Mol Neurodegener. 2022. PMID: 35313950 Free PMC article. Review.
3,109 results